What is AGEN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.35B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for AGEN?

P/E (TTM) is 3.76 and 52-week range is $2.71 to $10.31 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s AGEN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for AGEN?

The company profile lists revenue (TTM) near $134M, net income (TTM) near $93M, EPS (TTM) near $2.65 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Agenus Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Lexington, Massachusetts, US, 41.6M shares outstanding, ISIN US00847G8042 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Agenus Inc

$AGEN

Health Care · Biotechnology

IR Run Scenarios

$7.67

+1.72%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.

Employees

Website

agenusbio.com/

IPO

2000-02-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)